Table 1.
Clinical characteristics of Covid-19 patients and control subjects.
| Control subjects | COVID-19 patients | p | |
|---|---|---|---|
| N. | 91 | 182 | |
| Age (years) | 61.7 ± 10.3 | 63.9 ± 14.4 | 0.142 |
| BMI (kg/m2) | 26.1 ± 3.5 | 27.5 ± 9.0 | 0.389 |
| Male sex | 65% | 60% | 0.511 |
| Arterial hypertension | 53% | 49% | 0.608 |
| Smokers | 16% | 15% | 0.861 |
| COPD | 4% | 12% | 0.049 |
| Diabetes | 15% | 21% | 0.328 |
| CAD | 8% | 21% | 0.005 |
| PAD | 5% | 11% | 0.129 |
| Heart failure | 3% | 13% | 0.015 |
| Atrial fibrillation | 6% | 9% | 0.471 |
| ACE-inhibitors/ARBs | 40% | 35% | 0.427 |
| sNox2-dp (pg/ml) | 18 [12-27] | 33 [24-43] | <0.001 |
Legend: ACE: angiotensin converting enzyme, ARBs: angiotensin receptor blockers, BMI: body mass index, CAD: coronary heart disease, COPD: chronic obstructive pulmonary disease, sNox2-dp: serum Nox2-derived peptide. Differences between percentages were assessed by Fisher exact tests. All continuous variables were tested for normality with the Shapiro-Wilk test. Student unpaired t-test was used for normally distributed continuous variables (expressed as mean ± SD). Mann-Whitney U test was used for not-normally distributed continuous variables (expressed as median[interquartile range]).